Literature DB >> 16277271

[The degradation of p27 and cancer].

Shuhei Kotoshiba1, Keiichi Nakayama.   

Abstract

The cell cycle of eukaryotic cells is regulated by a series of protein complexes composed of cyclins and cyclin-dependent kinases (CDKs), the activity of which is suppressed by a group of CDK inhibitors (CKIs). Among the CKIs, p27 plays a pivotal role in the control of cell proliferation. Degradation of p27 is a critical event for reentry of cells into the cell cycle from G0 phase and occurs through ubiquitination by two ubiquitin ligase complexes (KPC and SCFSkP2) and subsequent degradation by the 26S-proteasome. A tumor suppressing function of p27 has been demonstrated in mouse models and studies of human tumors. This review will focus on the regulation of p27 proteolysis and its consequences for tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16277271

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  4 in total

1.  Tanshinone IIA inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt/Skp2/p27-associated pathway.

Authors:  Ying Luo; Dun-Quan Xu; Hai-Ying Dong; Bo Zhang; Yi Liu; Wen Niu; Ming-Qing Dong; Zhi-Chao Li
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

2.  Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Authors:  Vinayak Khattar; Jaideep V Thottassery
Journal:  J Cancer Ther       Date:  2013-10-01

3.  CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.

Authors:  Jian Luo; Yongjun Chen; Qiang Li; Bing Wang; Yanqiong Zhou; Hongzhen Lan
Journal:  Int J Mol Med       Date:  2016-06-07       Impact factor: 4.101

4.  TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway.

Authors:  Shu-Yang Wang; Ke Gao; Dan-Ling Deng; Juan-Juan Cai; Zhi-Yuan Xiao; Liu-Qing He; Hong-Li Jiao; Ya-Ping Ye; Run-Wei Yang; Ting-Ting Li; Li Liang; Wen-Ting Liao; Yan-Qing Ding
Journal:  Oncotarget       Date:  2016-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.